Research suggests that the nerve injury itself is to blame. Itch-sensing nerves, much like pain-sensing ones, can go haywire ...

Experts at SICP 2025 outline how molecular mechanisms and bedside assessments can guide personalised treatment for ...

Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length ...

The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ). On December 11, 2025, OKYO Pharma Limited ...

Shares of Okyo Pharma were higher Thursday after the company reported favorable nerve-restoration data for its drug that treats neuropathic corneal pain. Shares climbed 15% to $2.32 and are up twofold ...

Udupi: After six years of sustained research and clinical validation, the laser shoe, a novel, non-invasive therapy device for people living with type.

SNS Insider Highlights U.S. Neuropathic Pain Market Growth, Projected to Reach USD 5.47 Billion by 2033, Supported by Advanced Healthcare Systems, Innovative Pain Management Solutions, and Strong ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

Researchers investigating the prevalence of vitamin D deficiency and insufficiency in individuals with chronic spinal cord injury assessed participants’ vitamin D levels using high-performance liquid ...

Brent Saunders returned to Bausch + Lomb in 2023 to help address unmet needs in eye care, focusing on innovation and ...